S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Bangladesh seeks China help to repatriate Rohingya refugees
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Bangladesh seeks China help to repatriate Rohingya refugees
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Bangladesh seeks China help to repatriate Rohingya refugees
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
What's in Democrats' big bill? Climate, health care, savings
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
Bangladesh seeks China help to repatriate Rohingya refugees
NASDAQ:CARA

Cara Therapeutics - CARA Stock Forecast, Price & News

$11.27
+0.83 (+7.95%)
(As of 08/5/2022 08:48 PM ET)
Add
Compare
Today's Range
$10.18
$11.31
50-Day Range
$7.73
$11.27
52-Week Range
$7.40
$18.93
Volume
644,400 shs
Average Volume
557,412 shs
Market Capitalization
$603.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.80

Cara Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
137.8% Upside
$26.80 Price Target
Short Interest
Bearish
15.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.39
Upright™ Environmental Score
News Sentiment
0.74mentions of Cara Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$32,580 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.29) to $0.20 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

670th out of 1,283 stocks

Pharmaceutical Preparations Industry

324th out of 615 stocks

CARA stock logo

About Cara Therapeutics (NASDAQ:CARA) Stock

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Cara Therapeutics Price Performance

Shares of CARA Stock traded up $0.83 during trading on Friday, reaching $11.27. The company's stock had a trading volume of 644,466 shares, compared to its average volume of 442,395. The company has a market capitalization of $603.96 million, a price-to-earnings ratio of -6.33 and a beta of 1.02. The stock's 50-day moving average price is $8.99 and its 200 day moving average price is $10.24. Cara Therapeutics has a 1-year low of $7.40 and a 1-year high of $18.93.

Cara Therapeutics (NASDAQ:CARA - Get Rating) last issued its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.04. The firm had revenue of $4.79 million during the quarter, compared to analysts' expectations of $15.82 million. During the same quarter in the prior year, the firm earned ($0.47) EPS. On average, sell-side analysts anticipate that Cara Therapeutics will post -1.29 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Cara Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, May 13th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $26.80.

Insider Transactions at Cara Therapeutics

In related news, Director Jeffrey L. Ives sold 3,600 shares of the company's stock in a transaction on Friday, July 15th. The shares were sold at an average price of $9.05, for a total value of $32,580.00. Following the completion of the sale, the director now owns 15,476 shares in the company, valued at approximately $140,057.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 3.20% of the company's stock.

Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARA Stock News Headlines

Cara Therapeutics Inc - Stock Chart
Calls A Much Safer Way To Buy Cara Therapeutics
Cara Therapeutics Q1 2022 Earnings Preview
See More Headlines
Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARA Company Calendar

Last Earnings
5/09/2022
Today
8/07/2022
Next Earnings (Confirmed)
8/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CARA
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.80
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+137.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-88,440,000.00
Pretax Margin
-358.88%

Debt

Sales & Book Value

Annual Sales
$23.03 million
Book Value
$4.25 per share

Miscellaneous

Free Float
51,876,000
Market Cap
$603.97 million
Optionable
Optionable
Beta
1.02

Key Executives














CARA Stock - Frequently Asked Questions

Should I buy or sell Cara Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cara Therapeutics stock.
View analyst ratings for Cara Therapeutics
or view top-rated stocks.

What is Cara Therapeutics' stock price forecast for 2022?

4 equities research analysts have issued 12 month price objectives for Cara Therapeutics' stock. Their CARA stock forecasts range from $20.00 to $30.00. On average, they expect Cara Therapeutics' stock price to reach $26.80 in the next twelve months. This suggests a possible upside of 137.8% from the stock's current price.
View analysts' price targets for Cara Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Cara Therapeutics' stock performed in 2022?

Cara Therapeutics' stock was trading at $12.18 at the start of the year. Since then, CARA stock has decreased by 7.5% and is now trading at $11.27.
View the best growth stocks for 2022 here
.

When is Cara Therapeutics' next earnings date?

Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Cara Therapeutics
.

How can I listen to Cara Therapeutics' earnings call?

Cara Therapeutics will be holding an earnings conference call on Monday, August 8th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) posted its quarterly earnings data on Monday, May, 9th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.04. The biopharmaceutical company earned $4.79 million during the quarter, compared to analysts' expectations of $15.82 million. During the same quarter in the previous year, the firm posted ($0.47) EPS.

What other stocks do shareholders of Cara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pinnacle Associates Ltd. (1.39%), Victory Capital Management Inc. (0.25%), IQ EQ FUND MANAGEMENT IRELAND Ltd (0.25%), Royce & Associates LP (0.19%), New York State Teachers Retirement System (0.15%) and Los Angeles Capital Management LLC (0.13%). Company insiders that own Cara Therapeutics stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Mani Mohindru, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends for Cara Therapeutics
.

How do I buy shares of Cara Therapeutics?

Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $11.27.

How much money does Cara Therapeutics make?

Cara Therapeutics (NASDAQ:CARA) has a market capitalization of $603.96 million and generates $23.03 million in revenue each year. The biopharmaceutical company earns $-88,440,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis.

How many employees does Cara Therapeutics have?

Cara Therapeutics employs 84 workers across the globe.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The official website for Cara Therapeutics is www.caratherapeutics.com. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at janhavi.mohite@sternir.com, or via fax at 203-567-1510.

This page (NASDAQ:CARA) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.